William Blair, Jefferies Maintain LNTH Lantheus Holdings March 2026: Outperform Buy

On March 17, 2026 William Blair and Jefferies both maintained ratings on Lantheus Holdings, Inc. (LNTH). This LNTH analyst rating update left William Blair at Outperform and Jefferies at Buy, with Jefferies raising its price target to $110. We review both calls, what they mean for investors, and how the moves link to recent stock performance. The stock has moved -7.72% (-$6.21) since the events, and market cap stands at $4,922,986,324.

What the LNTH analyst rating updates say

Both analyst notes were issued on March 17, 2026 and were maintenance calls rather than fresh upgrades or downgrades. William Blair kept an Outperform stance, signaling continued confidence in Lantheus’ pipeline and approval prospects. Jefferies maintained a Buy rating while raising its price target to $110, reflecting better risk-reward expectations.

Each firm framed its view differently. William Blair highlighted regulatory timing and approval probabilities after a PDUFA date extension. Jefferies cited valuation and longer-term earnings upside tied to product commercialization.

Jefferies action and the LNTH analyst rating details

Jefferies issued its note at 03:08 PM ET on March 17, 2026 and left the rating at Buy while raising the price target to $110. This move signals that Jefferies sees upside from current levels and values Lantheus’ pipeline and revenue trajectory.

Jefferies’ maintained Buy and higher target typically supports investor confidence in a rebound scenario. For more detail see the analyst note source.

William Blair action and the LNTH analyst rating context

William Blair published its note at 05:13 PM ET on March 17, 2026 and maintained Outperform, labeling the company “optimistic” about eventual approval after a PDUFA extension. The firm emphasized approval probability rather than changing its underlying model.

William Blair’s stance suggests the firm expects clinical and regulatory outcomes to favor Lantheus, which supports a constructive view despite short-term volatility. Read the full comment source.

Implications for investors from the LNTH analyst rating

Maintained ratings mean analysts are not shifting conviction sharply left or right. Jefferies raising its $110 target while keeping Buy suggests higher expected upside versus current trading levels. Investors should see this as continued analyst support, not a new catalyst.

However, the company’s share move of -7.72% (-$6.21) since the notes shows market sensitivity to regulatory timing. Short-term traders may face volatility. Long-term investors should weigh approval timing, commercialization plans, and cash flow projections.

Historical analyst coverage and price context for LNTH analyst rating

Lantheus has drawn steady coverage from mid‑cap healthcare analysts, including Jefferies and William Blair. Historically these firms have favored Buy or Outperform stances when product approval probability and commercial potential align with valuation.

Today’s maintained calls fit that pattern: analysts stayed constructive while monitoring regulatory milestones. With a market cap of $4,922,986,324, LNTH sits in the mid‑cap healthcare group that reacts strongly to regulatory news and earnings beats.

Meyka AI grade, market view, and next steps for LNTH analyst rating

Meyka AI rates LNTH with a grade of A. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade signals overall strength but is not a guarantee and does not replace investor due diligence.

We recommend tracking upcoming regulatory notices, quarterly guidance, and any updated analyst notes. For our real-time tracking and AI analysis, see Lantheus on Meyka’s stock page.

Final Thoughts

The LNTH analyst rating updates on March 17, 2026 show continued analyst confidence rather than a directional shift. William Blair kept Outperform and pointed to approval odds after a PDUFA date extension. Jefferies stayed at Buy and raised its price target to $110, signaling expected upside from current levels. The stock has moved -7.72% (-$6.21) since the notes, underscoring near‑term sensitivity to regulatory timing. Investors should view these maintained ratings as confirmation of analyst conviction while weighing approval timing and execution risk. Meyka AI rates LNTH with a grade of A; this grade combines benchmark comparison, sector strength, financial trends, and analyst sentiment. Use this analysis as part of a broader decision process, and watch for new filings, earnings, and any revised analyst guidance that could alter consensus

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.